Most revenue comes from distributing pharmaceutical and third-party diagnostic products and from environmental laboratory testing, while the strategic focus and growth investment sit in carrier Ethernet and edge virtualisation networking equipment and in advanced encryption platforms sold to telecom operators and a long-standing government customer. Proprietary diagnostics earns from placing instruments on lease or low-margin sale alongside recurring reagent agreements; reported profit for the year was also lifted materially by capital gains on business disposals rather than by trading.
